Best Practice & Research Clinical Rheumatology
Volume 23, Issue 1 , Pages 49-58, February 2009

The preclinical stages of RA: lessons from human studies and animal models

  • Hani El-Gabalawy, MD, FRCPC (Professor of Medicine and Immunology)

      Affiliations

    • Corresponding Author InformationTel.: +1 204 787 2208.

University of Manitoba, RR149-800 Sherbrook Street, Winnipeg, Manitoba, Canada, R3A-1M4

Rheumatoid arthritis (RA) is a systemic autoimmune disorder based in the synovium of peripheral joints. Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs) are autoantibodies detectable in the majority of patients, with the latter being highly specific for RA. Retrospective studies utilizing preclinical serum samples have demonstrated that RF and ACPAs are detectable in the serum of RA patients months to years before disease onset. Moreover, a close association between ACPAs, smoking, and disease-predisposing HLA-DRB1 alleles has been identified, suggesting that these risk factors may converge to precipitate autoantibody-positive RA. Animal models of RA have added considerable information regarding the immune events that precede joint inflammation. These models have demonstrated that autoantibodies to ubiquitous antigens can directly precipitate chronic organ-specific inflammation centred in the joint. Furthermore, it has recently been possible to demonstrate a role for ACPAs in the animal models of RA. The major challenge currently is to develop a robust predictive model for RA onset, identifying the factors that serve to initiate, amplify, and mature the immune responses towards citrullinated autoantigens. Recent data from a high-risk population of RA family members indicate that the nature and specificity of the ACPA response in healthy individuals differs considerably from that in RA patients, and support the concept that this autoimmune response evolves over time and leads to the onset of clinically detectable synovitis. Ultimately, the availability of data from prospective studies of RA onset will allow for novel strategies that can potentially prevent disease in high-risk individuals.

Keywords: rheumatoid arthritis, autoantibodies, preclinical, predictive models

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6942(08)00133-2

doi:10.1016/j.berh.2008.11.004

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 1 , Pages 49-58, February 2009